J 2022

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO et. al.

Basic information

Original name

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

Authors

MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO, Veronika SKUCIOVA, Sandra Hurta CSIZMAR, Veronika MESTANOVA, Martin PEC, Marian ADAMKOV, Raghad Khalid AL-ISHAQ, Karel ŠMEJKAL (203 Czech Republic, belonging to the institution), Frank A GIORDANO, Dietrich BUSSELBERG, Kamil BIRINGER, Olga GOLUBNITSCHAJA and Peter KUBATKA

Edition

EPMA JOURNAL, Cham, SPRINGER INT PUBL AG, 2022, 1878-5077

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 6.500

RIV identification code

RIV/00216224:14160/22:00129768

Organization unit

Faculty of Pharmacy

UT WoS

000782529800001

Keywords in English

Breast cancer; Phytochemicals; Individualized patient profiling; Modifiable risk factors; Health risk assessment; Molecular patterns; Predictive Preventive Personalized Medicine (PPPM/3PM); Primary secondary tertiary care; Treated cancer; COVID-19

Tags

Tags

International impact, Reviewed
Změněno: 20/4/2023 17:05, JUDr. Sabina Krejčiříková

Abstract

V originále

Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals’ and patients’ needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.